-
1 . Academic Journal
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
- 저자
- by Falcone, Alfredo; Lonardi, Sara; De Braud, Filippo Guglielmo Maria; Bordonaro, Roberto; Maiello, Evaristo, et al.
- 소스
- In The Lancet Oncology April 2020 21(4):497-507